联合用药治疗绝经期妇女骨质疏松症临床研究

摘要

Objective To investigate the clinical effect of the comprehensive treatment to postmenopausal women with osteoporosis. Methods A retrospective analysis and discussion of patients' data of postmenopausal women with osteoporosis in 120 cases treated with miacalcic, fosamax joint premarin and 120 cases treated with miacalcic joint fosamax was done. Results After 3 months of treatment,bone density,BGP of the triple treatment group were obviously higher than the control group, while ALP and NTX were significantly lower than the control group,the differences of which have statistical significance( P <0. 05 ). Markedly effective in 32 cases, effective in 62 cases, and invalid in 7 cases were observed in the treatment group; while the corresponding of the control group were 75 cases,38 cases and 7 cases. Rank sum test showed the difference between the two groups was statistically significant P <0. 05 ). Conclusion Miacalcic, fosamax joint premarin treatment has good effect for menopause osteoporosis with mild adverse reactions and good patient compliance,thus is worth of the clinical development and promotion.%目的 探讨联合用药治疗绝经后妇女骨质疏松症的临床疗效.方法 随机选取盐城市亭湖区人民医院近两年来采用三联用药(密盖息、福善美、倍美力)和二联用药(密盖息、福善美)治疗绝经后妇女骨质疏松症各120例病历资料进行回顾性分析和讨论.结果 治疗3个月后将治疗后三联组的骨密度、BGP、显著高于对照组,而ALP和NTX均显著低于对照组,两组间的差异均具有统计学意义(P<0.05).三联组显效32例、有效62例、无效7例,对照组显效75例、有效38例、无效7例,经秩和检验显示两组间的差异有统计学意义(P<0.05).结论 使用密盖息、福善美联合倍美力治疗绝经期妇女骨质疏松症,疗效较佳,不良反应较轻,患者依从性好,值得临床开展和推广.